InspireMD (NYSE:NSPR) Receives New Coverage from Analysts at StockNews.com

StockNews.com assumed coverage on shares of InspireMD (NYSE:NSPR) in a report issued on Thursday. The firm issued a sell rating on the stock.

InspireMD Price Performance

NYSE:NSPR opened at $2.50 on Thursday. InspireMD has a 12-month low of $1.81 and a 12-month high of $3.85. The firm has a market capitalization of $62.33 million, a P/E ratio of -3.28 and a beta of 0.95. The stock’s fifty day simple moving average is $2.38 and its 200-day simple moving average is $2.50.

InspireMD (NYSE:NSPR) last issued its quarterly earnings data on Tuesday, May 14th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.06). The business had revenue of $1.51 million for the quarter, compared to analyst estimates of $1.38 million. InspireMD had a negative return on equity of 55.12% and a negative net margin of 350.35%. During the same period in the previous year, the business posted ($0.53) EPS. As a group, equities research analysts expect that InspireMD will post -0.82 earnings per share for the current year.

Institutional Trading of InspireMD

A hedge fund recently bought a new stake in InspireMD stock. McKinley Carter Wealth Services Inc. purchased a new stake in InspireMD, Inc. (NYSE:NSPR) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 10,000 shares of the company’s stock, valued at approximately $28,000. Institutional investors own 44.78% of the company’s stock.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.